培美曲塞与吉非替尼二线治疗晚期NSCLC的对比研究

目的 比较培美曲塞与吉非替尼单药二线治疗晚期NSCLC患者的疗效及不良反应.方法 将符合入组标准的患者75例随机分成培美曲塞组38例和吉非替尼组37例进行治疗观察,主要评价指标为ORR,DCR,生活质量改善率及不良反应.结果 培美曲塞组ORR为13.2％、DCR为47.4％,而吉非替尼组的ORR为18.9％,DCR为56.8％,两组差异无统计学意义(P＞0.05),但吉非替尼组的血液学毒性明显低于培美曲塞组(P＜0.05),症状改善及生活质量改善优于培美曲塞组(P＜0.05).结论 培美曲塞和吉非替尼单药二线治疗晚期非小细胞肺癌效率相近,但吉非替尼不良反应轻微,对症状和生活质量的改善率更高.

Comparison of efficacy of pemetrexed and gefitinib as second-line therapy in treatment of patients with advanced non small cell lung cancer

Objective To compare the antitumor efficacy and toxicity of pemetrexed and gifitinib in treatment of advanced non small lung cancer patients who had failed to previous chemotherapy.Methods A tatol of 75 patients met the criteria were randomly divided into pemetrexed group（n=38） and gefitinib group（n=37）.The overall response rate and side effects and improvemem rate of quality of life were observed and compared.Results In pemetexed group the overall response（ORR） was 13.2% and disease control rate（DCR） was 47.4%,and that in the gefitinib group were 18.9% and 56.8%,respectively,withour showing sgnificant difference,between the two groups（P0.05）.The hematologic toxicity in gefitinib group was sigificantly lower than that of pemetrexed group and improvement rate of quality of life was higher in patients of gefitinib group than that of the pemetrexed group（P0.05）.Conclusion As the second-line therapy gefitinib and pemetrexed are both efficacious in treatment of patients with advanced non small cell lung cancer.The toxicity was lower and the improvement rate of quality of life was higher in gefitinib group.